Royal Bank Of Canada Forecasts Strong Price Appreciation for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Posted by Geri Gentry on Nov 2nd, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price lifted by equities researchers at Royal Bank Of Canada from $810.00 to $913.00 in a note issued to investors on Monday, Benzinga reports. The brokerage presently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada‘s price objective would indicate a potential downside of 5.71% from the stock’s current price.

Several other equities analysts also recently commented on the stock. Zacks Research raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 28th. UBS Group raised Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $660.00 to $978.00 in a research report on Thursday, October 15th. Argus upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 price target for the company in a research note on Thursday, October 1st. Wells Fargo & Company upped their price target on Regeneron Pharmaceuticals from $750.00 to $925.00 and gave the stock an “equal weight” rating in a research note on Monday. Finally, Truist Financial increased their price objective on Regeneron Pharmaceuticals from $772.00 to $780.00 and gave the company a “buy” rating in a report on Wednesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $890.97.

Get Our Latest Research Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Stock Up 4.4%

Shares of REGN traded up $40.40 during mid-day trading on Monday, hitting $968.29. 637,215 shares of the company’s stock were exchanged, compared to its average volume of 821,362. The firm has a fifty day moving average of $793.30 and a two-hundred day moving average of $738.05. Regeneron Pharmaceuticals has a twelve month low of $591.52 and a twelve month high of $972.06. The stock has a market cap of $99.70 billion, a price-to-earnings ratio of 21.35, a P/E/G ratio of 1.57 and a beta of 0.10. The company has a quick ratio of 3.66, a current ratio of 4.06 and a debt-to-equity ratio of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The business had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $4.58 billion. During the same quarter last year, the firm earned $11.83 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 36.3% on a year-over-year basis. On average, sell-side analysts forecast that Regeneron Pharmaceuticals will post 49.10 earnings per share for the current year.

Insider Activity

In other news, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the sale, the director directly owned 603 shares of the company’s stock, valued at approximately $512,550. This trade represents a 39.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $1,032,750.00. Following the completion of the transaction, the executive vice president owned 13,134 shares in the company, valued at $11,163,900. The trade was a 8.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 8,093 shares of company stock worth $6,506,845 in the last 90 days. Insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Orbimed Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at $11,358,000. BlackRock Inc. bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth $5,682,636,000. Contravisory Investment Management Inc. bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth $6,327,000. Oxbow Advisors LLC bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth $3,342,000. Finally, Deutsche Bank AG acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $323,249,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Positive Sentiment: Strong Q3 results: Regeneron reported earnings of $20.07 per share, well above the $16.51 analyst consensus, while revenue rose 36% year over year to approximately $5.1 billion. Earnings growth of about 70%, strong Dupixent sales and a larger Sanofi profit share are reinforcing investor confidence. These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 Results
Positive Sentiment: Analysts raised targets: Guggenheim lifted its target to $1,100 and initiated a “buy” view, while JPMorgan raised its target to $1,050 with an “overweight” rating. Bank of America increased its target to $1,030 and kept a “buy” rating; broader analyst forecasts reportedly reach as high as $1,175. Regeneron Pharmaceuticals Analyst Forecasts
Positive Sentiment: Pipeline and commercial momentum: Investors are also responding to the company’s deep pipeline, encouraging Libtayo data in high-risk skin cancer and an expanded BARDA supply agreement for an Ebola treatment. Why Regeneron Shares Are In Focus After Strong Earnings
Positive Sentiment: Shareholder returns: Regeneron declared a quarterly dividend of $0.94 per share, payable December 3, and continues repurchases under its buyback program.

Regeneron Pharmaceuticals Company Profile

(Get Free Report)

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.